Viking Therapeutics (0VQA) Income Statement
Viking Therapeutics Income Statement
Last quarter (Q3 2026), Viking Therapeutics's total revenue was $0.00. In Q3, Viking Therapeutics's net income was $-183.19M. See Viking Therapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ -431.00K | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 393.34M | $ 150.92M | $ 100.83M | $ 70.36M | $ 55.68M | |
| Depreciation and Amortization | $ 431.00K | $ 346.00K | $ 292.00K | $ 291.00K | $ 296.00K |
| $ -359.15M | $ -109.52M | $ -85.52M | $ -68.52M | $ -54.68M | |
| $ -393.34M | $ -150.92M | $ -100.83M | $ -70.36M | $ -55.68M | |
| $ 33.70M | $ 40.96M | $ 14.93M | $ 1.49M | $ 692.00K | |
| $ -359.64M | $ -109.96M | $ -85.89M | $ -68.87M | $ -54.99M | |
| $ -359.64M | $ -109.96M | $ -85.89M | $ -68.87M | $ -54.99M | |
| Per Share Metrics | |||||
| Basic EPS | $ -3.19 | $ -1.01 | $ -0.91 | $ -0.88 | $ -0.70 |
| Diluted EPS | $ -3.19 | $ -1.01 | $ -0.91 | $ -0.88 | $ -0.70 |
| Weighted Average Shares Outstanding | 112.67M | 109.04M | 94.35M | 76.83M | 77.20M |
| Weighted Average Shares Outstanding (Diluted) | 112.67M | 109.04M | 94.35M | 76.83M | 77.20M |
Currency in USD